Sign in to view content

Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study

Priya Sharma Vakharia, MD

Video
Published 2023

Related

Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Updates from the Field
2019
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Subgroup Analyses of the Phase 1 DAVIO Trial of EYP-1901 Showing Reduced Treatment Burden in Wet Age-related Macular Degeneration
Philip P Storey, MD, MPH
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more